The effects of peripherally-subacute treatment with irisin on hippocampal dendritogenesis and astrocyte-secreted factors
Fibronectin type III domain containing 5 (FNDC5)/irisin is an exercise-induced myokine, which contributes to cognitive functions. However, the relationship between the neuroprotective effects of FNDC5/irisin and hippocampal dendritic remodeling and astrocyte-secreted factors remains unclear. Therefo...
Saved in:
Published in | Journal of exercise nutrition & biochemistry Vol. 23; no. 4; pp. 32 - 35 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
한국운동영양학회
31.12.2019
|
Subjects | |
Online Access | Get full text |
ISSN | 2233-6842 2233-6834 2233-6842 |
DOI | 10.20463/jenb.2019.0029 |
Cover
Loading…
Summary: | Fibronectin type III domain containing 5 (FNDC5)/irisin is an exercise-induced myokine, which contributes to cognitive functions. However, the relationship between the neuroprotective effects of FNDC5/irisin and hippocampal dendritic remodeling and astrocyte-secreted factors remains unclear. Therefore, we explored whether subchronic recombinant irisin treatment affected hippocampal morphology and some astrocyte-derived molecules.
Mice were intraperitoneally injected with irisin (0.5 μg/kg/day) for seven days, followed by their sacrifice two days later. Hippocampal morphometric parameters were analyzed and pgc-1a, fndc5, bdnf, and some astrocyte-derived factors mRNA levels were measured.
Dendritic length, arborization, and spine density were enhanced by irisin regimen in hippocampal CA1 and CA3 areas. Hippocampal pgc-1a, fndc5, and bdnf mRNA levels were significantly increased by irisin treatment. Moreover, hevin mRNA levels were significantly enhanced, whereas tgf-b1 levels downregulated by irisin treatment.
FNDC5/irisin has dendritogenic activity probably through hevin induction and TGF-β1 suppression. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2233-6842 2233-6834 2233-6842 |
DOI: | 10.20463/jenb.2019.0029 |